--First data disclosure from Ribometrix’s RNA-targeting drug discovery platform identifies small molecules targeting c-MYC, a validated but historically undruggable cancer driver -- --Data shows ...

Oncogenes control cell proliferation and are proposed regulators of fetal development. C-myc codes for a nuclear protein that is necessary in the positive regulation of cell proliferation. When c-myc ...

The c-Myc oncoprotein is frequently overexpressed in human cancers and is essential for cancer cell proliferation. The dysregulation of ubiquitin-proteasome-mediated degradation is one of the ...

The DNA is part of the c-MYC gene, which, when improperly regulated, is the main driver of all blood cancers and 80% of human solid tumors. The MYC oncogene plays a significant role in cancer ...

Series D extends runway into 2027, advancing first-in-class c-mod DPTX3186 toward proof-of-concept in gastric cancer.Strong ...

Unless otherwise listed, all solvents and reagents were purchased from Aldrich Chemical Co. (MO, USA) and used as received. Anhydrous chloroform and methanol were purchased from Aldrich Chemical Co.

Preliminary safety and activity of perioperative triplet chemotherapy plus bevacizumab (bev) in patients with borderline resectable colorectal cancer liver metastases (CLM). Final phase II trial ...

Suzhou Kintor Pharmaceuticals Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising cereblon (CRBN) binding moiety covalently linked to Myc proto-oncogene protein (c-Myc), ...

The Innovation Center of NanoMedicine (Director General: Prof. Kazunori Kataoka, Location: Kawasaki in Japan, Abbreviation: iCONM) reported in ACS Nano (Impact Factor: 14.588 in 2019) together with ...